Skip to main content

Table 2 Adherence and persistence at 12 months (%) in “incident” subjects following a pharmacological treatment for chronic diseases, adjusted by age and stratified by gender and tertile of deprivation

From: Socio-economic inequalities in the use of drugs for the treatment of chronic diseases in Italy

  

Tertiles of deprivation

Incidents (n)

Adherence (%)a

Adherence adjusted for age %

Adherence adjusted for age and DI %

Relative difference between Adherence adjusted for age and adjusted for age and DI

Persistance (%)b

Persistance adjusted for age %

Persistance %2

Relative difference between Persistance adjusted for age and adjusted for age and DI

Hypertension

Men (≥ 18 year)

1

152,364

58.7 (56,9–60,6)

57.8

57.9

0.1%

53.4 (53,1–53,6)

54.2

54.2

0.0%

2

160,629

58.4 (56,6–60,2)

54.6 (54,4–54,8)

3

177,145

56.5 (54,9–58,3)

54.4 (54,2–54,7)

Women (≥ 18 year)

1

159,560

49.5 (47,9–51,1)

48.5

48.5

0.1%

44.1 (43,9–44,4)

45.0

45.0

0.0%

2

167,975

49.2 (47,7–50,8)

45.5 (45,3–45,7)

3

176,907

47.0 (45,5–48,5)

45.4 (45,2–45,6)

Dyslipidemia

Men (≥ 18 year)

1

103,990

53.8 (52,8–54,8)

51.9

52.1

0.4%

53.8 (53,5–54,1)

51.8

51.7

-0.1%

2

112,564

52.7 (51,7–53,6)

52.8 (52,5–53,1)

3

137,595

50.0 (49,1–50,8)

49.3 (49,1–49,6)

Women (≥ 18 year)

1

103,113

42.3 (41,4–43,2)

40.5

40.8

0.6%

44.2 (43,9–44,5

43.4

43.4

0.1%

2

114,359

41.3 (40,5–42,1)

44.2 (43,9–44,5)

3

146,235

38.8 (38,1–39,5)

42.1 (41,9–42,4)

Osteoporosis

Men (≥ 18 year)

1

5,056

72.0 (69,6–74,4)

67.8

67.8

0.1%

49.5 (48,1–50,9)

43.4

43.0

-0.9%

2

4,969

68.2 (65,9–70,5)

44.5 (43,2–45,9)

3

5,212

63.6 (61,5–65,8)

36.6 (35,3–37,9)

Women (≥ 18 year)

1

39,514

71.4 (70,0–73,0)

69.8

70.1

0.4%

55.4 (54,9–55,9)

51.8

51.9

0.2%

2

44,308

70.7 (69,2–72,1)

53.0 (52,6–53,5)

3

54,808

68.2 (66,9–69,7)

48.3 (47,8–48,7)

Diabetes

Men (≥ 18 year)

1

36,431

41.9 (39,9–43,9)

37.6

38.0

1.2%

44.0 (43,5–44,5)

43.2

43.2

0.0%

2

43,054

37.4 (35,6–39,1)

42.7 (42,3–43,2)

3

54,985

35.0 (33,5–36,5)

43.1 (42,7–43,5)

Women (≥ 18 year)

1

29,196

37.1 (35,2–39,2)

31.6

32.2

1.8%

38.3 (37,8–38,9)

36.8

36.8

0.0%

2

39,911

31.9 (30,4–33,6)

36.0 (35,5–36,4)

3

50,436

28.3 (27,0–29,7)

36.5 (36,1–37,0)

COPD

Men (≥ 18 year)

1

40,013

37.1 (35,8–38,5)

36.1

36.4

0.8%

24.8 (24,4–25,3)

23.7

23.7

0.0%

2

46,773

37.2 (36,0–38,5)

25.0 (24,6–25,4)

3

67,152

34.8 (33,8–35,8)

22.2 (21,9–22,5)

Women (≥ 18 year)

1

42,549

32.1 (30,9–33,3)

30.5

30.7

0.7%

19.9 (19,5–20,3)

18.0

18.0

-0.2%

2

52,046

31.2 (30,2–32,3)

18.9 (18,6–19,3)

3

70,427

29.0 (28,2–29,9)

16.2 (15,9–16,5)

  1. aHigh adherence, calculated by MPR, was defined as therapeutic coverage ≥ 75% of the observation period (median (IQR): 284 (139–337)). The percentages were adjusted by age (see statistical methods for further details)
  2. bPersistence to treatment was assessed in the 365 days following the first prescription (data index). An interruption to treatment occurs if the subject does not have a prescription delivered within 60 days (assessed on the basis of DDD). The percentages were adjusted by age (see statistical methods for more details)